BIAF
$2.74
bioAffinity Technologies, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates thro...
Recent News
BC-Most Active Stocks
YY Group Holdings Ltd. 64,558,078 0.055
BIAF vs. GH: Which Cancer Detection Stock Is the Better Buy Now?
bioAffinity leans on its CyPath Lung sputum test for early lung cancer detection, while Guardant Health expands liquid biopsy and screening. Which strategy is ahead? Let's see.
BIAF Stock Dips After Q3 Earnings Reflect Lower Sales and Wider Loss
bioAffinity's third-quarter 2025 performance shows lower sales and a wider loss as it pivots to focus on CyPath Lung and expands VA system adoption.
BIAF Stock Down Following Q2 Earnings Despite CyPath Lung Growth
bioAffinity shifts its focus on CyPath Lung as the second-quarter 2025 loss widens, with rising adoption and new market expansion underway.
The Zacks Analyst Blog Highlights Meta Platforms, ServiceNow, Booking, Vaso and bioAffinity Technologies
META, NOW, and BKNG lead with AI-driven growth and digital transformation tailwinds, while VASO and BIAF offer speculative upside.